Who is the CEO of Gaudium IVF and Women Health Ltd?
- Answer Field
-
Dr. Peeyush Khanna is the Whole-Time Director and Dr. Manika Khanna is the Key Promoter of the company.
Gaudium IVF and Women Health Limited has launched its book-building IPO, scheduled to open from February 20 to February 24, 2026, with listing proposed on BSE and NSE on February 27, 2026. The issue is priced in the band of ₹75 to ₹79 per share with a face value of ₹5 per share and a lot size of 189 shares. The total issue size comprises 2,08,86,200 equity shares aggregating up to ₹165 crore, including a fresh issue of 1,13,92,500 shares (up to ₹90 crore) and an offer for sale of 94,93,700 shares (up to ₹75 crore). The public offering is structured as a combination of fresh capital and offer for sale under the book-building route.
Gaudium IVF and Women Health Limited operates in the assisted reproductive technology and women’s healthcare segment, providing IVF and related fertility treatments across multiple centres in India. Investors can apply for the IPO through the ASBA (Application Supported by Blocked Amount) facility available via their bank’s net-banking portal. Applicants need to select the Gaudium IVF and Women Health Limited IPO from the list of active issues, enter the bid quantity and price within the specified range, and authorise the blocking of funds in their bank account. The blocked amount remains in the account until the allotment process is completed. Upon finalisation of allotment, shares, if allotted, are credited to the investor’s demat account and the corresponding amount is debited, while any unallotted portion is released.
Applications can also be submitted through the UPI mechanism using a supported trading or investment platform. After placing the bid, investors receive a mandate request on their UPI application, which must be approved within the stipulated timeline to validate the application. Funds remain blocked until the allotment status is determined, following which the release or adjustment of funds takes place in accordance with the IPO process.
For more details, visit the Gaudium IVF and Women Health Limited IPO page.
Details | Information |
IPO Date | Feb 20, 2026 to Feb 24, 2026 |
Issue Size | 2,08,86,200 shares (agg. up to ₹165 Cr) |
Price Band | ₹75 to ₹79 per share |
Lot Size | 189 Shares |
Listing At | BSE, NSE |
Funding capital expenditure towards establishment of New IVF Centers of the Company
Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company
General Corporate Expenses
Event | Date |
IPO Open Date | Fri, Feb 20, 2026 |
IPO Close Date | Tue, Feb 24, 2026 |
Tentative Allotment | Wed, Feb 25, 2026 |
Initiation of Refunds | Wed, Feb 25, 2026 |
Credit of Shares to Demat | Thu, Feb 26, 2026 |
Tentative Listing Date | Fri, Feb 27, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Tue, Feb 24, 2026 |
₹75 to ₹79 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 1 | 189 | ₹14,931 |
Individual investors (Retail) (Max) | 13 | 2,457 | ₹1,94,103 |
S-HNI (Min) | 14 | 2,646 | ₹2,09,034 |
S-HNI (Max) | 66 | 12,474 | ₹9,85,446 |
B-HNI (Min) | 67 | 12,663 | ₹10,00,377 |
The Gaudium IVF and Women Health Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate Gaudium IVF and Women Health Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 189 shares) within the price band of ₹75 to ₹79 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Gaudium IVF and Women Health IPO is structured in accordance with the book-building regulations applicable to mainboard public issues. The reservation framework specifies the proportion of the net issue available to Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Individual Investors (RIIs). The distribution is expressed as a percentage of the net issue and outlines the minimum and maximum allocation thresholds for each category.
Investor Category | Shares Offered |
QIB Shares Offered | Not more than 50.00% of the Net Issue |
Retail Shares Offered | Not less than 35.00% of the Net Issue |
NII Shares Offered | Not less than 15.00% of the Net Issue |
This structure reflects the reservation norms disclosed for the issue and indicates the proportion of shares available to each investor segment under the book-building process.
Total Assets: Increased from ₹36.63 crore in FY23 to ₹106.62 crore as of Sept 2025.
Total Income: Recorded at ₹49.75 crore in Sept 2025, as compared to ₹44.26 crore in FY23.
Profit After Tax (PAT): Reported at ₹12.51 crore in Sept 2025, and ₹13.53 crore in FY23.
Net Worth: Recorded at ₹58.85 crore in Sept 2025 in comparison to ₹22.73 crore in FY23.
Reserves and Surplus: Stood at ₹28.16 crore in Sept 2025, as compared to ₹21.74 crore in FY23.
EBITDA: Stood at ₹18.95 crore in Sept 2025 in comparison to ₹20.07 crore in FY23.
The company’s asset base has expanded over the review period, reflecting scaling of operations and alignment of resources with business requirements.
Income levels have shown movement across reporting periods, indicating operational activity and participation within its service segment.
Profitability has remained positive across the reviewed periods, reflecting sustained earnings generation.
The net worth position has strengthened over time, supported by retained earnings and overall balance sheet growth.
Reserves have increased over the review period, contributing to the company’s capital base and financial stability.
Operating performance, as reflected in earnings before interest, tax, depreciation and amortisation, indicates continued operating-level performance across reporting periods.
Overall financial movement suggests progression in operational scale and strengthening of the balance sheet during the review period.
The company operates in the assisted reproductive technology (ART) and fertility treatment segment, where performance may be influenced by regulatory developments, clinical compliance requirements, and evolving healthcare standards.
Demand for IVF and related fertility procedures can be affected by economic conditions, treatment affordability, and changing patient preferences, which may influence revenue visibility.
The business is dependent on medical professionals, embryologists, and specialised healthcare staff. Any challenges in retaining skilled personnel could impact service delivery and operational continuity.
Expansion across multiple centres requires consistent quality control and infrastructure management, and variations in centre-level performance may affect overall operating outcomes.
Rising awareness of assisted reproductive technology, delayed parenthood trends, and increasing maternal age support long-term demand growth in the IVF segment.
Expansion through a hub-and-spoke model enables wider geographic reach while centralising specialised capabilities, potentially supporting scalability.
Growing acceptance of fertility treatments among domestic and international patients may contribute to patient inflow across centres.
Advancements in reproductive technology and broader healthcare access may strengthen the company’s participation within the evolving fertility care ecosystem.
KPI | Sept 30, 2025 | Mar 31, 2025 |
ROE | 21.25% | 41.31% |
ROCE | 21.03% | 39.70% |
Debt/Equity | 0.38 | 0.41 |
RoNW | 21.34% | 41.71% |
PAT Margin | 25.14% | 26.96% |
EBITDA Margin | 38.29% | 40.48% |
Price to Book Value | — | 10.48 |
Registrar | Lead Manager(s) |
Bigshare Services Pvt.Ltd. | Sarthi Capital Advisors Pvt.Ltd. |
Gaudium IVF & Women Health Ltd.
B1/51, Janak Puri,
B-1, New Delhi, New Delhi, 110058
Phone: 011-4885 8585
Email: compliance@gaudiumivfcentre.com
Website: https://www.gaudiumivfcentre.com/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Gaudium IVF and Women Health IPO allotment status.
No result found
Dr. Peeyush Khanna is the Whole-Time Director and Dr. Manika Khanna is the Key Promoter of the company.
The Gaudium IVF and Women Health IPO is scheduled to open for subscription on February 20, 2026, and will close on February 24, 2026, as per the disclosed issue timeline.
The company operates in the assisted reproductive technology (ART) and fertility care segment, providing services such as IVF, ICSI, IUI, and related reproductive healthcare treatments through a hub-and-spoke model. Long-term sustainability depends on demand for fertility services, regulatory compliance, availability of medical expertise, and operational scalability across centres, as outlined in the offer documents.
The IPO comprises 2,08,86,200 equity shares aggregating up to ₹165 crore, including a fresh issue of up to ₹90 crore and an offer for sale of up to ₹75 crore.
‘Pre-apply’ refers to a facility that allows investors to place their IPO application before the issue opens. The bid is processed once the subscription window becomes active, subject to the platform’s procedures.
The IPO has a lot size of 189 shares. Retail investors can bid for a minimum of one lot (189 shares) and in multiples thereof within the specified price band.
The tentative allotment date for the IPO is February 25, 2026, according to the disclosed schedule.
The registrar to the issue is Bigshare Services Pvt.Ltd., which is responsible for processing applications, allotment, and related investor services.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
The application can be made through the ASBA facility via a bank’s net-banking platform or through the UPI mechanism using a supported trading application. Investors need to enter bid details, authorise fund blocking, and confirm the mandate within the specified timeline.
Yes, a Demat account is required to receive shares in case of allotment, as equity shares are credited electronically.
After the allotment process is finalised, investors can check the allotment status through the registrar’s website or their trading platform, and allotted shares, if any, are credited to the Demat account while unutilised funds are released.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading